Table 4.
HER2 overexpression in patient subgroups stratified by hormone receptor and BRMS1 status
| Patient subgroup | HER2 positive | HER2 negative |
|---|---|---|
| ER (P = 0.001) | ||
| ER+/BRMS1+ | 9 of 145 (6%) | 136 of 145 (94%) |
| ER+/BRMS1− | 7 of 42 (17%) | 35 of 42 (83%) |
| ER−/BRMS1+ | 9 of 33 (27%) | 24 of 33 (73%) |
| ER−/BRMS1− | 5 of 17 (29%) | 12 of 17 (71%) |
| PR (P = 0.01) | ||
| PR+/BRMS1+ | 7 of 117 (6%) | 110 of 117 (94%) |
| PR+/BRMS1− | 4 of 27 (15%) | 23 of 27 (85%) |
| PR−/BRMS1+ | 11 of 61 (18%) | 50 of 61 (82%) |
| PR−/BRMS1− | 8 of 32 (25%) | 24 of 32 (75%) |